Skip to main content
Erschienen in: Die Innere Medizin 6/2011

01.06.2011 | Schwerpunkt

Therapiestrategien bei Vaskulitiden

Entsprechend den Empfehlungen der European League Against Rheumatism (EULAR) und der European Vasculitis Study Group (EUVAS)

verfasst von: Dr. J.U. Holle, F. Moosig, W.L. Gross

Erschienen in: Die Innere Medizin | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Zusammenfassung

In den letzten Jahren wurden vor allem für die primär systemischen Vaskulitiden Krankheits- und Aktivitätsstadien definiert und eine Reihe kontrollierter Studien durchgeführt, die heute eine evidenzbasierte stadien- und aktivitätsabhängige Therapie ermöglichen. Auf der Basis kontrollierter Studien wurden 2009 Empfehlungen zur Diagnostik und Therapie der Autoimmunvaskulitiden durch die EULAR (European League Against Rheumatism) bzw. EUVAS (European Vasculitis Study Group) erarbeitet und veröffentlicht. Der Artikel fasst die aktuellen Studien zusammen, die zu den europäischen Leitlinien zum Management der Vaskulitiden geführt haben, und gibt außerdem Aufschluss über neuere Studien, die nach Veröffentlichung der europäischen Therapieempfehlungen publiziert worden sind.
Literatur
1.
Zurück zum Zitat Cohen P, Pagnoux C, Mahr A et al (2007) Churg-Strauss syndrome with poor prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 57:686–693PubMedCrossRef Cohen P, Pagnoux C, Mahr A et al (2007) Churg-Strauss syndrome with poor prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 57:686–693PubMedCrossRef
2.
Zurück zum Zitat Ferri C, Mascia MT (2006) Cryoglobulinemic vasculitis. Curr Opin Rheumatol 18: 54–63PubMed Ferri C, Mascia MT (2006) Cryoglobulinemic vasculitis. Curr Opin Rheumatol 18: 54–63PubMed
3.
Zurück zum Zitat Groot K de, Harper L, Jayne DR et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150:670–680PubMed Groot K de, Harper L, Jayne DR et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150:670–680PubMed
4.
Zurück zum Zitat Groot K de, Rasmussen N, Bacon PA et al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:2461–2469PubMedCrossRef Groot K de, Rasmussen N, Bacon PA et al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:2461–2469PubMedCrossRef
5.
Zurück zum Zitat Guillevin L, Durand-Gasselin B, Cevallos R et al (1999) Microscopic Polyangiitis. Clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42:421–430PubMedCrossRef Guillevin L, Durand-Gasselin B, Cevallos R et al (1999) Microscopic Polyangiitis. Clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42:421–430PubMedCrossRef
6.
Zurück zum Zitat Hellmich B, Flossman O, Gross WL et al (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66:605–617PubMedCrossRef Hellmich B, Flossman O, Gross WL et al (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66:605–617PubMedCrossRef
7.
Zurück zum Zitat Hiemstra TF, Walsh M, Mahr A et al; European Vasculitis Study Group (EUVAS) (2010) Mycophenolate mofetil versus azathioprine for remission maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A randomized controlled trial. JAMA 304:2381–2388PubMedCrossRef Hiemstra TF, Walsh M, Mahr A et al; European Vasculitis Study Group (EUVAS) (2010) Mycophenolate mofetil versus azathioprine for remission maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A randomized controlled trial. JAMA 304:2381–2388PubMedCrossRef
8.
Zurück zum Zitat Hoffman GS, Cid MC, Rendt-Zagar KE et al; Infliximab-GCA Study Group (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146:621–630PubMed Hoffman GS, Cid MC, Rendt-Zagar KE et al; Infliximab-GCA Study Group (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146:621–630PubMed
9.
Zurück zum Zitat Holle JU, Gross WL (2009) ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy. J Autoimmun 32:163–171PubMedCrossRef Holle JU, Gross WL (2009) ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy. J Autoimmun 32:163–171PubMedCrossRef
10.
Zurück zum Zitat Holle JU, Gross WL, Holl-Ulrich K et al (2010) Prospective longterm follow-up of localized Wegener’s granulomatosis: Does it occur as persistent disease stage? Ann Rheum Dis 69:907–914 Holle JU, Gross WL, Holl-Ulrich K et al (2010) Prospective longterm follow-up of localized Wegener’s granulomatosis: Does it occur as persistent disease stage? Ann Rheum Dis 69:907–914
11.
Zurück zum Zitat Holle JU, Gross WL, Latza U et al (2011) Improved outcome of 445 Wegener’s granulomatosis patients in a German vasculitis center over four decades. Arthritis Rheum 63:257–266PubMedCrossRef Holle JU, Gross WL, Latza U et al (2011) Improved outcome of 445 Wegener’s granulomatosis patients in a German vasculitis center over four decades. Arthritis Rheum 63:257–266PubMedCrossRef
12.
Zurück zum Zitat Jayne DR, Chapel H, Adu D et al (2000) Intravenous immunoglobulin for ANCA-asscociated systemic vasculitis with persistent disease activity. QJM 93:433–439PubMedCrossRef Jayne DR, Chapel H, Adu D et al (2000) Intravenous immunoglobulin for ANCA-asscociated systemic vasculitis with persistent disease activity. QJM 93:433–439PubMedCrossRef
13.
Zurück zum Zitat Jayne DR, Gaskin G, Rasmussen N et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18:2180–2188PubMedCrossRef Jayne DR, Gaskin G, Rasmussen N et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18:2180–2188PubMedCrossRef
14.
Zurück zum Zitat Johnston SL, Loock RJ, Gompels MM (2002) Takayasu arteritis. A review. J Clin Pathol 55:481–486PubMedCrossRef Johnston SL, Loock RJ, Gompels MM (2002) Takayasu arteritis. A review. J Clin Pathol 55:481–486PubMedCrossRef
15.
Zurück zum Zitat Jones R, Tervaert JW, Hauser T et al (2010) Rituximab versus cyclophosphamide for ANCA-associated renal vasculitis. N Engl J Med 363:211–220PubMedCrossRef Jones R, Tervaert JW, Hauser T et al (2010) Rituximab versus cyclophosphamide for ANCA-associated renal vasculitis. N Engl J Med 363:211–220PubMedCrossRef
16.
Zurück zum Zitat Klemmer PJ, Chalermskulrat W, Reif MS et al (2003) Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 42:1149–1153PubMedCrossRef Klemmer PJ, Chalermskulrat W, Reif MS et al (2003) Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 42:1149–1153PubMedCrossRef
17.
Zurück zum Zitat Little MA, Nightingale P, Verburgh CA et al (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69:1036–1043PubMedCrossRef Little MA, Nightingale P, Verburgh CA et al (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69:1036–1043PubMedCrossRef
18.
Zurück zum Zitat Mahr AD, Jover JA, Spiera RF et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56:2789–2797PubMedCrossRef Mahr AD, Jover JA, Spiera RF et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56:2789–2797PubMedCrossRef
19.
Zurück zum Zitat Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L et al (2008) A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 67:625–630PubMedCrossRef Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L et al (2008) A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 67:625–630PubMedCrossRef
20.
Zurück zum Zitat Mazlumzadeh M, Hunder GG, Easley KA et al (2006) Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 54:3310–3318PubMedCrossRef Mazlumzadeh M, Hunder GG, Easley KA et al (2006) Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 54:3310–3318PubMedCrossRef
21.
Zurück zum Zitat Metzler C, Hellmich B, Gause A et al (2004) Churg Strauss syndrome – successful induction of remission with methotrexate and unecpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 22(Suppl):S52–S61PubMed Metzler C, Hellmich B, Gause A et al (2004) Churg Strauss syndrome – successful induction of remission with methotrexate and unecpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 22(Suppl):S52–S61PubMed
22.
Zurück zum Zitat Metzler C, Miehle N, Manger K et al (2007) Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener‚s granulomatosis. Rheumatology 46:1087–1091PubMedCrossRef Metzler C, Miehle N, Manger K et al (2007) Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener‚s granulomatosis. Rheumatology 46:1087–1091PubMedCrossRef
23.
Zurück zum Zitat Moosig F, Butherus K, Hellmich B, Gross WL (2010) Mepolizumab, a monoclonal anti-IL-5 antibody, has steroid-sparing properties. Arthritis Rheum 62:S925 [abstract] Moosig F, Butherus K, Hellmich B, Gross WL (2010) Mepolizumab, a monoclonal anti-IL-5 antibody, has steroid-sparing properties. Arthritis Rheum 62:S925 [abstract]
24.
Zurück zum Zitat Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68:310–317PubMedCrossRef Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68:310–317PubMedCrossRef
25.
Zurück zum Zitat Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68:318–323PubMedCrossRef Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68:318–323PubMedCrossRef
26.
Zurück zum Zitat Narvaez J, Bernad B, Roig-Vilaseca D et al (2007) Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum 37:13–19PubMedCrossRef Narvaez J, Bernad B, Roig-Vilaseca D et al (2007) Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum 37:13–19PubMedCrossRef
27.
Zurück zum Zitat Pagnoux C, Mahr A, Hamidou MA et al (2008) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359:2790–2803PubMedCrossRef Pagnoux C, Mahr A, Hamidou MA et al (2008) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359:2790–2803PubMedCrossRef
28.
Zurück zum Zitat Ribi C, Cohen P, Pagnoux C et al (2008) Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 58:586–594PubMedCrossRef Ribi C, Cohen P, Pagnoux C et al (2008) Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 58:586–594PubMedCrossRef
29.
Zurück zum Zitat Sablé-Fourtassou R, Cohen P, Mahr A et al (2005) Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143:632–638PubMed Sablé-Fourtassou R, Cohen P, Mahr A et al (2005) Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143:632–638PubMed
30.
Zurück zum Zitat Salvarani C, Cantini F, Hunder GG (2008) Polymyalgia rheumatic and giant cell arteritis. Lancet 372:234–245PubMedCrossRef Salvarani C, Cantini F, Hunder GG (2008) Polymyalgia rheumatic and giant cell arteritis. Lancet 372:234–245PubMedCrossRef
31.
Zurück zum Zitat Schmidt WA, Seigert A, Gromnica-Ihle et al (2008) Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology 47:96–101PubMedCrossRef Schmidt WA, Seigert A, Gromnica-Ihle et al (2008) Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology 47:96–101PubMedCrossRef
32.
Zurück zum Zitat Segelmark M, Selga D (2007) The challenge of managing patients with polyarteritis nodosa. Curr Opin Rheumatol 19:33–38PubMedCrossRef Segelmark M, Selga D (2007) The challenge of managing patients with polyarteritis nodosa. Curr Opin Rheumatol 19:33–38PubMedCrossRef
33.
Zurück zum Zitat Sinico R, di Toma L, Maggiore U et al (2005) Prevalence and clinical signficance of Antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 52:2926–2935PubMedCrossRef Sinico R, di Toma L, Maggiore U et al (2005) Prevalence and clinical signficance of Antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 52:2926–2935PubMedCrossRef
34.
Zurück zum Zitat Stanson AW, Friese JL, Johnson CM et al (2001) Polyarteritis nodosa: Spectrum of angiographic findings. Radiographics 21:151–159PubMed Stanson AW, Friese JL, Johnson CM et al (2001) Polyarteritis nodosa: Spectrum of angiographic findings. Radiographics 21:151–159PubMed
35.
Zurück zum Zitat Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for the induction of remission in ANCA-associated vasculitis: a randomized controlled trial (RAVE). N Engl J Med 363:221–232PubMedCrossRef Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for the induction of remission in ANCA-associated vasculitis: a randomized controlled trial (RAVE). N Engl J Med 363:221–232PubMedCrossRef
36.
Zurück zum Zitat Stone JH; Wegener’s granulomatosis etanercept trial research group (2003) Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum 48:2299–2309PubMedCrossRef Stone JH; Wegener’s granulomatosis etanercept trial research group (2003) Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum 48:2299–2309PubMedCrossRef
37.
Zurück zum Zitat Van der Goes MC, Jacobs JW, Boers M et al (2010) Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 69:1913–1919CrossRef Van der Goes MC, Jacobs JW, Boers M et al (2010) Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 69:1913–1919CrossRef
38.
Zurück zum Zitat Walsh M, Merkel PA, Mahr A et al (2010) Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res 62:1166–1173CrossRef Walsh M, Merkel PA, Mahr A et al (2010) Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res 62:1166–1173CrossRef
Metadaten
Titel
Therapiestrategien bei Vaskulitiden
Entsprechend den Empfehlungen der European League Against Rheumatism (EULAR) und der European Vasculitis Study Group (EUVAS)
verfasst von
Dr. J.U. Holle
F. Moosig
W.L. Gross
Publikationsdatum
01.06.2011
Verlag
Springer-Verlag
Erschienen in
Die Innere Medizin / Ausgabe 6/2011
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI
https://doi.org/10.1007/s00108-010-2772-5

Weitere Artikel der Ausgabe 6/2011

Die Innere Medizin 6/2011 Zur Ausgabe

Mitteilungen des BDI

Mitteilungen des BDI

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.